- Home
- NSIT vs TARS Comparison
NSIT vs TARS Comparison
Compare NSIT & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSIT | TARS |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NSIT | TARS |
|---|---|---|
| Price | $82.94 | $68.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $118.75 | $89.00 |
| AVG Volume (30 Days) | 327.7K | ★ 564.4K |
| Earning Date | 05-07-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 4.86 | N/A |
| Revenue | ★ $8,247,180,000.00 | $451,360,000.00 |
| Revenue This Year | $3.79 | $56.26 |
| Revenue Next Year | $2.16 | $26.47 |
| P/E Ratio | $17.06 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $77.10 | $38.51 |
| 52 Week High | $160.68 | $85.25 |
Technical Indicators
Market Signals| Indicator | NSIT | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 43.56 |
| Support Level | $79.24 | $65.62 |
| Resistance Level | $88.04 | $78.34 |
| Average True Range (ATR) | 2.98 | 3.35 |
| MACD | -0.28 | -0.29 |
| Stochastic Oscillator | 32.87 | 18.49 |
Price Performance
Historical ComparisonAbout NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.